Azra Durak-Nalbantić

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Guy De Backer, Piotr Jankowski, Kornelia Kotseva et al. · Atherosclerosis · 2019 · 350 citations · Full text

Cardiovascular Epidemiology, Cardiovascular Disease, Coronary Artery Disease +9

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 285 citations · Full text

Family Medicine, Metabolic Syndrome, Lipid Disorder +10

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 112 citations · Full text

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

Maciej Banach, Peter E. Penson, Michal Vráblík et al. · Pharmacological Research · 2021 · 96 citations · Full text

Hypertension, Optimal Use, Hyperlipidemia +23

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 32 citations · Full text